Search results
Results from the WOW.Com Content Network
The 340B Drug Pricing Program is a US federal government program created in 1992 that requires drug manufacturers to provide outpatient drugs to eligible health care organizations and covered entities at significantly reduced prices. The intent of the program is to allow covered entities to "stretch scarce federal resources as far as possible ...
The agency did not provide an estimate of how much ethanol would qualify. The pilot program covers ethanol produced in 2023 and 2024, and will be replaced by a new program in 2025 that biofuel ...
Low-income enrollees tend to have more chronic conditions than other enrollees. [21] Low-income subsidy enrollees represent about one-quarter of enrollment, [22] but about half of the program's retail drug spending. [2] Nearly 30% of Federal spending on Part D goes towards paying for the low-income subsidy. [23]
The Medicaid drug rebate for brand name drugs, paid by drug manufacturers to the states, is increased to 23.1% (except for the rebate for clotting factors and drugs approved exclusively for pediatric use, which increases to 17.1%), and the rebate is extended to Medicaid managed care plans; the Medicaid rebate for non-innovator, multiple source ...
In 2024, once your out-of-pocket spending reaches $8,000 (including certain payments made on your behalf, like through the Extra Help program), you’ll automatically get “catastrophic coverage ...
The Federal Employees Health Benefits (FEHB) Program is a system of "managed competition" through which employee health benefits are provided to civilian government employees and annuitants of the United States government. The government contributes 72% of the weighted average premium of all plans, not to exceed 75% of the premium for any one ...
A U.S. appeals court revived a lawsuit on Friday by healthcare and drug industry groups challenging the first-ever U.S. law requiring pharmaceutical companies to negotiate drug prices with the ...
The Medicaid Drug Rebate Program is a program in the United States that was created by the Omnibus Budget Reconciliation Act of 1990 (OBRA'90). The program establishes mandatory rebates that drug manufacturers must pay state Medicaid agencies related to the dispensing of outpatient prescription drugs covered by Medicaid .